Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07413679 · ClinicalTrials.gov registry record
Long-term Safety of Danicopan: IPIG Registry-based Cohort Study
A clinical trial of Paroxysmal Nocturnal Hemoglobinuria and PNH, sponsored by Alexion Pharmaceuticals.
- Active
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT07413679: Active study of Paroxysmal Nocturnal Hemoglobinuria and PNH, sponsored by Alexion Pharmaceuticals.
NCT07413679 is a study of Paroxysmal Nocturnal Hemoglobinuria and PNH that is active but no longer recruiting, run by Alexion Pharmaceuticals. The registered enrollment target is 50 participants, below the 261-participant average among 14 other Paroxysmal Nocturnal Hemoglobinuria trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07413679, a study of Paroxysmal Nocturnal Hemoglobinuria and PNH, is active but no longer recruiting, sponsored by Alexion Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a noninterventional cohort study using primary and secondary data from the International PNH Interest Group (IPIG) PNH registry. It is designed to characterize the long-term safety and tolerability of danicopan as add-on therapy to eculizumab or ravulizumab in adult participants with PNH.
Conditions Studied
Interventions
- DRUG Danicopan
Study Locations (1)
Massachusetts
- Alexion Pharmaceuticals, Inc. (Sponsor) - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-08-18 |
| Est. Completion | 2029-07-01 |
What the registry record for NCT07413679 still lists
NCT07413679 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 261-participant average among 14 other Paroxysmal Nocturnal Hemoglobinuria trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Paroxysmal Nocturnal Hemoglobinuria appearing as the primary indexed condition, and to 1 intervention - of which Danicopan is the first listed.
NCT07413679 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07413679 about?
NCT07413679 is a clinical study titled "Long-term Safety of Danicopan: IPIG Registry-based Cohort Study". This is a noninterventional cohort study using primary and secondary data from the International PNH Interest Group (IPIG) PNH registry. It is designed to characterize the long-term safety and tolerability of danicopan as add-on therapy to eculizumab or ravulizumab in adult participants with PNH.
What is the current status of trial NCT07413679?
This trial is currently active not recruiting. The enrollment target is 50 participants. The study started on 2025-08-18. Estimated completion is 2029-07-01.
What conditions does trial NCT07413679 study?
This clinical trial studies the following conditions: Paroxysmal Nocturnal Hemoglobinuria, PNH.
What interventions are being tested in trial NCT07413679?
The interventions under investigation include: Danicopan (DRUG).
Who is sponsoring clinical trial NCT07413679?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07413679 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Nocturnal Hemoglobinuria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07413679's enrollment target sits among peer trials
50 10th of 14 higher than 3 of 14 other Paroxysmal Nocturnal Hemoglobinuria trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Paroxysmal Nocturnal Hemoglobinuria trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The International PNH Interest Group PNH Registry
RECRUITING
-
Home Reported Outcomes in PNH
RECRUITING
-
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
RECRUITING · Phase 3
-
Global PNH Patient Registry
RECRUITING
-
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
RECRUITING · Phase 2
-
Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI